Rissel, Florian
Objectif : le suivi pharmacologique des anticorps monoclonaux utilisés en thérapeutique, notamment des anti-TNF-α et des anticorps-anti-médicaments dans les maladies chroniques intestinales est un outil pratique clinique. À ce titre il fallait évaluer et comparer les tests disponibles pour adapter nos pratiques au laboratoire. Matériel et méthodes ...
Martinez, Kelly
L’adalimumab est un anticorps monoclonal anti-tumor necrosis factor alpha (TNFα) utilisé dans les pathologies inflammatoires chroniques comme les maladies inflammatoires chroniques de l’intestin. Son dosage est effectué au laboratoire d’immunologie au CHU de Montpellier, dans le cadre du suivi thérapeutique pharmacologique. Cette analyse constitue ...
Bessissow, Talat Nguyen, Geoffrey C Tarabain, Osman Peyrin-Biroulet, Laurent Foucault, Nathalie McHugh, Kevin Ruel, Joannie
Published in
World Journal of Gastroenterology
BACKGROUND A gap remains in documenting the impact of anti-tumor necrosis factor therapy on disease burden in ulcerative colitis (UC) patients treated in a real-world setting. The use of patient-reported outcomes (PROs) has been discussed as a primary endpoint in the context of the FDA PRO Guidance, for labelling purposes. Specifically, the efficac...
d'Haens, Geert Sandborn, William Loftus, Edward Hanauer, Stephen Schreiber, Stefan Peyrin‐biroulet, Laurent Panaccione, Remo Panés, Julián Baert, Filip Colombel, Jean-Frederic
...
Background & aims: Dose-optimization strategies for biologic therapies in Crohn's disease (CD) are not well established. The SERENE CD (Study of a Novel Approach to Induction and Maintenance Dosing With Adalimumab in Patients With Moderate to Severe Crohn's Disease) trial evaluated higher vs standard adalimumab induction dosing and clinically adjus...
Panés, Julián Colombel, Jean-Frederic d'Haens, Geert Schreiber, Stefan Panaccione, Remo Peyrin‐biroulet, Laurent Loftus, Edward Danese, Silvio Tanida, Satoshi Okuyama, Yusuke
...
Background & aims: SERENE UC (Study of a Novel Approach to Induction and Maintenance Dosing With Adalimumab in Patients With Moderate to Severe Ulcerative Colitis) evaluated the efficacy of higher adalimumab induction and maintenance dose regimens in patients with ulcerative colitis.Methods: This phase 3, double-blind, randomized trial included ind...
Ben-Horin, Shomron Novack, Lena Mao, Ren Guo, Jing Zhao, Yue Sergienko, Ruslan Zhang, Jian Kobayashi, Taku Hibi, Toshifumi Chowers, Yehuda
...
Background and aims: Starting biologic treatment early in the course of inflammatory bowel disease (IBD) may be associated with higher efficacy, especially in Crohn's disease (CD).Methods: This was a systematic review and individual-patient data meta-analysis of all placebo-controlled trials of biologics approved for IBD at study inception (October...
Kirchgesner, Julien Desai, Rishi Schneeweiss, Maria Beaugerie, Laurent Kim, Seoyoung Schneeweiss, Sebastian
Purpose: To calibrate real-world evidence (RWE) against randomized controlled trials (RCTs) in ulcerative colitis (UC) by replicating the SUCCESS trial on the effectiveness of infliximab in patients with UC, using U.S. and French healthcare claims data. Methods: The SUCCESS trial showed improved remission with infliximab and thiopurines combined co...
Peyrin-Biroulet, Laurent Loftus, Edward Colombel, Jean-Frédéric Danese, Silvio Rogers, Raquel Bornstein, Jeffrey Chen, Jingjing Schreiber, Stefan Sands, Bruce Lirio, Richard
...
VARSITY (An Efficacy and Safety Study of Vedolizumab Intravenous [IV] Compared to Adalimumab Subcutaneous [SC] in Participants With Ulcerative Colitis) showed superior clinical remission and endoscopic improvement in ulcerative colitis with vedolizumab vs adalimumab. This analysis compared histologic outcomes. / ClinicalTrials.gov NCT02497469; Eudr...
Combe, Bernard Kivitz, Alan Tanaka, Yoshiya van der Heijde, Désirée Simon, J Abraham Baraf, Herbert S B Kumar, Uma Matzkies, Franziska Bartok, Beatrix Ye, Lei
...
Published in
Annals of the rheumatic diseases
To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active rheumatoid arthritis (RA) despite ongoing treatment with methotrexate (MTX). This 52-week, multicentre, double-blind, placebo-controlled and active-controlled phase III tria...
Reinisch, Walter Gecse, Krisztina Halfvarson, Jonas Irving, Peter M Jahnsen, Jørgen Peyrin-Biroulet, Laurent Rogler, Gerhard Schreiber, Stefan Danese, Silvio
Published in
Inflammatory bowel diseases
The introduction of tumor necrosis factor (TNF) inhibitors has significantly changed the treatment landscape in Crohn's disease (CD). The overall therapeutic achievements with TNF inhibitors such as infliximab, adalimumab, and certolizumab pegol paved the way to push the boundaries of treatment goals beyond symptomatic relief and toward cessation o...